MND Genetic Cause: 1 in 4 Patients | King's College London Study
King's College London researchers identify genetic causes in 25% of MND cases via massive rare variant analysis, revolutionizing diagnosis and treatment prospects.
No reviews yet. Be the first to rate Ahmad!
Dr Ahmad Al Khleifat is a Senior Research Fellow at King’s College London. He trained in medicine in Egypt and earned his MSc and PhD in Clinical Neuroscience from King’s College London. He holds the MND Association Lady Edith Wolfson and ALS Association’s Milton Safenowitz Senior Fellowship. His research focuses on the application of big data and AI to precision medicine in motor neuron disease, including optimisation of clinical trials, drug discovery, complex disease genetics, structural variation analysis in genomics, and development of proteomic-based biomarkers for neurodegeneration.
Dr Al Khleifat chairs the Trans-Ancestral Genetics working group in Project MinE and leads the Drug Discovery and Trials Optimisation Working Group in the DEMON network. He co-founded the Alan Turing Institute Interest Group in Precision Dementia Medicine and the Alzheimer’s Association group on AI for Precision Dementia Medicine. He serves as EDI Theme Representative at the NIHR Maudsley BRC. He has received the ENCALS Young Investigator Award and King’s College London Recognition Awards. Key publications include Al Khleifat et al. (2021) on structural variation analysis of whole genome sequences in amyotrophic lateral sclerosis in NPJ Genomic Medicine, and Ashton et al. (2021) on plasma neurofilament light in Nature Communications. He is based in the Department of Basic and Clinical Neuroscience within the Institute of Psychiatry, Psychology and Neuroscience.
King's College London researchers identify genetic causes in 25% of MND cases via massive rare variant analysis, revolutionizing diagnosis and treatment prospects.